Cargando…
Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer’s disease
Acetylcholinesterase inhibitors are approved drugs currently used for the treatment of Alzheimer’s disease (AD) dementia. Basal forebrain cholinergic system (BFCS) atrophy is reported to precede both entorhinal cortex atrophy and memory impairment in AD, challenging the traditional model of the temp...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601919/ https://www.ncbi.nlm.nih.gov/pubmed/28916821 http://dx.doi.org/10.1038/s41598-017-09780-3 |
_version_ | 1783264486450266112 |
---|---|
author | Cavedo, Enrica Grothe, Michel J. Colliot, Olivier Lista, Simone Chupin, Marie Dormont, Didier Houot, Marion Lehéricy, Stephane Teipel, Stefan Dubois, Bruno Hampel, Harald |
author_facet | Cavedo, Enrica Grothe, Michel J. Colliot, Olivier Lista, Simone Chupin, Marie Dormont, Didier Houot, Marion Lehéricy, Stephane Teipel, Stefan Dubois, Bruno Hampel, Harald |
author_sort | Cavedo, Enrica |
collection | PubMed |
description | Acetylcholinesterase inhibitors are approved drugs currently used for the treatment of Alzheimer’s disease (AD) dementia. Basal forebrain cholinergic system (BFCS) atrophy is reported to precede both entorhinal cortex atrophy and memory impairment in AD, challenging the traditional model of the temporal sequence of topographical pathology associated with AD. We studied the effect of one-year Donepezil treatment on the rate of BFCS atrophy in prodromal AD patients using a double-blind, randomized, placebo-controlled trial of Donepezil (10 mg/day). Reduced annual BFCS rates of atrophy were found in the Donepezil group compared to the Placebo treated arm. Secondary analyses on BFCS subregions demonstrated the largest treatment effects in the Nucleus Basalis of Meynert (NbM) and the medial septum/diagonal band (Ch1/2). Donepezil administered at a prodromal stage of AD seems to substantially reduce the rate of atrophy of the BFCS nuclei with highest concentration of cholinergic neurons projecting to the cortex (NbM), hippocampus and entorhinal cortex (Ch1/2). |
format | Online Article Text |
id | pubmed-5601919 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-56019192017-09-20 Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer’s disease Cavedo, Enrica Grothe, Michel J. Colliot, Olivier Lista, Simone Chupin, Marie Dormont, Didier Houot, Marion Lehéricy, Stephane Teipel, Stefan Dubois, Bruno Hampel, Harald Sci Rep Article Acetylcholinesterase inhibitors are approved drugs currently used for the treatment of Alzheimer’s disease (AD) dementia. Basal forebrain cholinergic system (BFCS) atrophy is reported to precede both entorhinal cortex atrophy and memory impairment in AD, challenging the traditional model of the temporal sequence of topographical pathology associated with AD. We studied the effect of one-year Donepezil treatment on the rate of BFCS atrophy in prodromal AD patients using a double-blind, randomized, placebo-controlled trial of Donepezil (10 mg/day). Reduced annual BFCS rates of atrophy were found in the Donepezil group compared to the Placebo treated arm. Secondary analyses on BFCS subregions demonstrated the largest treatment effects in the Nucleus Basalis of Meynert (NbM) and the medial septum/diagonal band (Ch1/2). Donepezil administered at a prodromal stage of AD seems to substantially reduce the rate of atrophy of the BFCS nuclei with highest concentration of cholinergic neurons projecting to the cortex (NbM), hippocampus and entorhinal cortex (Ch1/2). Nature Publishing Group UK 2017-09-15 /pmc/articles/PMC5601919/ /pubmed/28916821 http://dx.doi.org/10.1038/s41598-017-09780-3 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Cavedo, Enrica Grothe, Michel J. Colliot, Olivier Lista, Simone Chupin, Marie Dormont, Didier Houot, Marion Lehéricy, Stephane Teipel, Stefan Dubois, Bruno Hampel, Harald Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer’s disease |
title | Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer’s disease |
title_full | Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer’s disease |
title_fullStr | Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer’s disease |
title_full_unstemmed | Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer’s disease |
title_short | Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer’s disease |
title_sort | reduced basal forebrain atrophy progression in a randomized donepezil trial in prodromal alzheimer’s disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601919/ https://www.ncbi.nlm.nih.gov/pubmed/28916821 http://dx.doi.org/10.1038/s41598-017-09780-3 |
work_keys_str_mv | AT cavedoenrica reducedbasalforebrainatrophyprogressioninarandomizeddonepeziltrialinprodromalalzheimersdisease AT grothemichelj reducedbasalforebrainatrophyprogressioninarandomizeddonepeziltrialinprodromalalzheimersdisease AT colliotolivier reducedbasalforebrainatrophyprogressioninarandomizeddonepeziltrialinprodromalalzheimersdisease AT listasimone reducedbasalforebrainatrophyprogressioninarandomizeddonepeziltrialinprodromalalzheimersdisease AT chupinmarie reducedbasalforebrainatrophyprogressioninarandomizeddonepeziltrialinprodromalalzheimersdisease AT dormontdidier reducedbasalforebrainatrophyprogressioninarandomizeddonepeziltrialinprodromalalzheimersdisease AT houotmarion reducedbasalforebrainatrophyprogressioninarandomizeddonepeziltrialinprodromalalzheimersdisease AT lehericystephane reducedbasalforebrainatrophyprogressioninarandomizeddonepeziltrialinprodromalalzheimersdisease AT teipelstefan reducedbasalforebrainatrophyprogressioninarandomizeddonepeziltrialinprodromalalzheimersdisease AT duboisbruno reducedbasalforebrainatrophyprogressioninarandomizeddonepeziltrialinprodromalalzheimersdisease AT hampelharald reducedbasalforebrainatrophyprogressioninarandomizeddonepeziltrialinprodromalalzheimersdisease AT reducedbasalforebrainatrophyprogressioninarandomizeddonepeziltrialinprodromalalzheimersdisease |